We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 57

Affirmed: No Individual Private Right of Action Under HIPAA
  • McGuireWoods LLP
  • USA
  • June 21 2018

In holding with long-established precedent, a federal judge held on June 15 that the Health Insurance Portability and Accountability Act (HIPAA) does

LabCorp settles with OFCCP for alleged bias in hiring and compensation
  • Constangy Brooks Smith & Prophete LLP
  • USA
  • September 14 2017

Laboratory Corporation of America has agreed to pay approximately $200,000 to resolve a matter with Office of Federal Contract Compliance Programs

Prometheus rises again
  • McDermott Will & Emery
  • USA
  • June 30 2011

After having certiorari vacated and being remanded back to the Federal Circuit in the wake of decision of the Supreme Court of the United States in Bilski v. Kappos, (see “Bilski v. KapposBack Where We Started?” and to IP Update Vol. 12, No. 7) the Supreme Court has again granted certiorari in Mayo Collaborative Services v. Prometheus Labs., Inc., Supreme Court Case No. 10-1150 (June 20, 2011) to consider the patent eligibility of a claim directed to a medical diagnostic test.

Back in the high court again: Prometheus v. Mayo
  • Morrison & Foerster LLP
  • USA
  • June 20 2011

Today, the Supreme Court granted Mayo’s petition for a writ of certiorari to review the Federal Circuit’s holding that Prometheus’s patent claims to clinical and diagnostic methods constitute patent-eligible subject matter.

Delaware Court of Chancery denies injunctive relief, instructs on deal protection provisions and disclosure of projections
  • Reed Smith LLP
  • USA
  • May 27 2011

In a letter opinion issued on May 12, 2011, the Delaware Court of Chancery declined to extend preliminary injunctive relief to plaintiff shareholders objecting to Laboratory Corporation of America Holdings, Inc.'s (LabCorp) acquisition of Orchid Cellmark Inc. (Orchid).

In re Orchid Cellmark Inc. S’holder Litig., C.A. No. 6373-VCN (Del. Ch. May 12, 2011) (V.C. Noble)
  • Potter Anderson & Corroon LLP
  • USA
  • May 18 2011

In this letter opinion, the Court of Chancery declined to enjoin a negotiated acquisition of Orchid Cellmark Inc. by way of a tender offer that was set to expire on May 17, 2011.

Getting the prescription right for patenting personalized medicine innovations
  • Fenwick & West LLP
  • USA
  • May 5 2011

"Personalized medicine" refers to the use of patient-specific information to better inform medical care.

Federal court rejects FTC attempt to stop medical laboratory merger
  • Sidley Austin LLP
  • USA
  • March 1 2011

On February 22, 2011, a federal district court in California denied a motion by the Federal Trade Commission (FTC) to issue a preliminary injunction against the proposed acquisition by Laboratory Corporation of America (LabCorp) of Westcliff Medical Laboratories (Westcliff).

Collateral estoppel bars Metabolite from “eating its cake”
  • McDermott Will & Emery
  • USA
  • February 28 2011

Addressing the issue of whether collateral estoppel will bar a patentee from collecting post-judgment royalties under a license agreement where the license was found to be terminated in a prior case, the U.S. Court of Appeals for the Tenth Circuit affirmed the district court’s holding that LabCorp was not liable to Metabolite for post-judgment royalties.

FTC challenges consummated acquisition previously approved by bankruptcy court
  • Fried Frank Harris Shriver & Jacobson LLP
  • USA
  • December 27 2010

On December 1, the Federal Trade Commission (“FTC”) issued an administrative complaint challenging Laboratory Corporation of America’s (“LabCorp”) consummated acquisition of rival Westcliff Medical Laboratories, Inc. (“Westcliff”).